en · de · es
semax-notes.peptides7250.com › Data › Semax Origin And Molecular Structure — Questions and Answers

Semax Origin And Molecular Structure — Questions and Answers

By Editorial Desk · published 2026-06-10 · last reviewed 2026-07-05 · Data

Everything below concerns heptapeptide. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.

Updated 2026-07-05. Numbers and descriptions here follow the published literature rather than marketing material.

Semax Origin and Molecular Structure

Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. It is described in the literature as an analogue of the ACTH(4–10) fragment, a short N-terminal portion of adrenocorticotropic hormone that retains some neurotropic activity without the full hormonal effects of the parent peptide. The molecule carries a methionine residue at the N-terminus and two proline residues near the C-terminus, features that shape both its interactions with receptor systems and its chemical stability. The free peptide corresponds to the formula C37H51N9O10S and a molecular mass near 813.9 Da.

The compound was developed in the 1980s at the Institute of Molecular Genetics in Moscow, where it emerged from research on short ACTH fragments and their effects on the central nervous system. Russian pharmaceutical listings describe it as a nootropic and neuroprotective agent, most often formulated as nasal drops. It is not a marketed medicine in the United States or the European Union, and no pharmacopoeial monograph covers it. Consequently, most published clinical experience with the substance originates from a small number of research centres, mainly in Russia and neighbouring countries.

Pharmacological accounts link semax to melanocortin signalling and to modulation of neurotrophic factor expression, particularly brain-derived neurotrophic factor and nerve growth factor. Much of this evidence comes from rodent studies using intranasal delivery, a route chosen because it allows peptides to reach the central nervous system with limited systemic exposure. Whether the same mechanisms operate in humans at comparable magnitude remains an open question. The precise receptor or receptors responsible for the reported behavioural and neuroprotective effects have not been conclusively identified.

Storage Handling and Analytical Verification

Semax is normally supplied as a lyophilized powder, and that form is the most stable. Suppliers commonly recommend storage at -20 °C in a desiccated container protected from light, with short-term handling at room temperature limited to weighing and transfer. Powder that has absorbed moisture degrades faster, so vials should be warmed to ambient temperature before opening to prevent condensation on the contents. Hygroscopic behavior is typical of short hydrophilic peptides, and humidity control matters more than temperature alone for long-term retention.

Once dissolved, the peptide is considerably less stable than the solid. Aqueous solutions are usually prepared at neutral to slightly acidic pH, filtered, and divided into single-use aliquots before freezing. Repeated freeze-thaw cycles are a common cause of avoidable loss and are best prevented by never refreezing a thawed aliquot. Adsorption to plastic and glass surfaces can lower the measured concentration of dilute solutions, particularly below roughly 0.1 mg/mL. Buffer choice, salt content, and container material all influence how much peptide remains detectable after storage.

Identity and purity are established with standard peptide methods. Reversed-phase HPLC with ultraviolet detection near 214 nm resolves the parent peak from deletion and truncation byproducts, and reports typically quote a main-peak percentage. Mass spectrometry by electrospray or MALDI-TOF confirms the expected molecular mass, while amino acid analysis or peptide mapping can verify composition when the sequence itself is in question. A certificate of analysis that pairs a chromatogram with a mass spectrum is more informative than a purity figure alone. Counter-ion content and residual solvents are separate specifications and are frequently omitted.

Semax at a glance

PropertyValueNotes
Molecular formulaC37H51N9O10SFree acid form of the heptapeptide; depends on terminal groups
Molecular massAbout 813.9 g/molAverage mass used for mass spectrometry confirmation
AppearanceWhite to off-white solidSupplied as a lyophilised powder; hygroscopic
Solubility classFreely soluble in aqueous mediaWater, saline, and phosphate buffers; limited organic solubility
Typical storage temperature-20 degrees CelsiusLong term and dry; short working periods may use 2 to 8 degrees Celsius

Background and Development

Semax is a synthetic heptapeptide developed in the Soviet Union during the 1980s by researchers at the Institute of Molecular Genetics in Moscow. It was designed as a truncated analog of adrenocorticotropic hormone, retaining only the fragment spanning residues four through ten. Investigators sought a peptide that would preserve the cognitive effects associated with ACTH while eliminating the hormonal stimulation of the adrenal cortex. The compound entered clinical use in Russia during the following decade.

Russian regulatory authorities approved the peptide for nasal administration, and it remains listed in the national pharmacopoeia under several trade names. Documented indications include acute ischemic stroke, transient ischemic attacks, traumatic brain injury, and certain ophthalmological and neurological conditions. Physicians also prescribe it for cognitive complaints in older patients, although the evidence base for that use is thinner. Outside Russia and a few neighboring states, the substance is not an approved medicine and is sold instead as a research chemical.

Related pages on this site

Analytical Methods and Stability Profile

Identity and purity of Semax are established mainly by reversed-phase high-performance liquid chromatography coupled with mass spectrometry. The chromatographic trace gives a purity estimate as a percentage of total peak area, while electrospray or matrix-assisted laser desorption ionization confirms the molecular mass against the calculated value. Amino acid analysis and sequence-specific fragmentation provide further confirmation when a supplier's chain of custody is unclear. Vendors frequently quote a purity figure without stating the detection wavelength or the integration method, which limits how far one number can be compared with another.

Stability depends heavily on physical state. Lyophilized powder held dry, cold and dark retains its content over long periods, whereas dissolved peptide begins to change within days at room temperature. The most cited degradation route is oxidation of the methionine residue, which converts the peptide to a sulfoxide form that elutes differently on chromatography. Hydrolysis of amide bonds and adsorption onto container walls contribute smaller losses. Buffers that exclude oxygen from the headspace slow the oxidation pathway, but no single condition prevents all change indefinitely.

Further detail

Advantages anticipated for this method is that the drug is transported without highly toxic compounds, the drug is released without harmful radiation or relying on a specific chemical reaction to occur and the drug can be selectively released at a target tissue. A second approach is to attach a chemotherapeutic drug directly to the functionalized surface of the silver nanoparticle combined with a nucelophilic species to undergo a displacement reaction. For example, once the nanoparticle drug complex enters or is in the vicinity of the target tissue or cells, a glutathione monoester can be administered to the site. The nucleophilic ester oxygen will attach to the functionalized surface of the nanoparticle through a new ester linkage while the drug is released to its surroundings. The drug is now active and can exert its biological function on the cells immediate to its surroundings limiting non-desirable interactions with other tissues.

Women were not simply spectators throughout the Independence Wars of Spanish America. Many women took sides on political issues and joined independence movements to participate on many different levels. Women could not help but act as caring relatives either as mother, sister, wives or daughters of the men who were fighting. Women created political organizations and organized meetings and groups to donate food and supplies to the soldiers. Some women supported the wars as spies, informants and combatants. Manuela Sáenz was a long term lover of Simón Bolívar and acted as his spy and confidante and was secretary of his archive. She saved his life on two occasions, nursed wounded soldiers and has even been believed some historians to have fought in a few battles. Sáenz followed Bolívar and his army through the independence wars and became known in Hispanic America as the "mother of feminism and women's emancipation and equal rights." Bolívar himself was a supporter of women's rights and suffrage in Hispanic America. It was Bolívar who allowed for Sáenz to become the great pioneer of women's freedom. He wanted to set the women of Hispanic America free from the oppression and inferiority of what the Spanish regime had established. Bolívar even made Sáenz a Colonel of the Colombian Army due to her heroics which caused controversy because there were no women in the army at the time. Another woman who gained prominence in the fight for independence was Juana Azurduy de Padilla, a mixed-race woman who fought for independence in the Río de la Plata region.

=== Cancer === The role of iron in cancer defense can be described as a "double-edged sword" because of its pervasive presence in non-pathological processes. People having chemotherapy may develop iron deficiency and anemia, for which intravenous iron therapy is used to restore iron levels. Iron overload, which may occur from high consumption of red meat, may initiate tumor growth and increase susceptibility to cancer onset, particularly for colorectal cancer.

Sources: en.wikipedia.org

Supporting material

Modimelanotide (INN; development code AP-214, ABT-719, and ZP-1480) is a melanocortinergic peptide drug derived from α-melanocyte-stimulating hormone (α-MSH) which was under development by, at different times, Action Pharma, Abbott Laboratories, AbbVie, and Zealand for the treatment of acute kidney injury. It acts as a non-selective melanocortin receptor agonist, with IC50 values of 2.9 nM, 1.9 nM, 3.7 nM, and 110 nM at the MC1, MC3, MC4, and MC5 receptors. Modimelanotide failed clinical trials for acute kidney injury despite showing efficacy in animal models, and development was not further pursued.

=== SARM1 === SARM1 is a Toll-like receptor protein and also functions as a intracellular NADase. Under normal circumstances NADase activity are inhibited in the presence of NAD+, where NAD+ binds to armadillo/heat motifs (ARMs), which inhibits the dimerization of the toll-like receptor domain that activates the NADase activity. If there are damages to the binding site of NAD+ or disruption that prevents the interaction between ARMs and the toll-like receptor domain, NADase activity will be turned on at a constitutive level. As a result SARM1 will have higher consumption of NAD+ and produce NADase products (ADP-ribose and nicotinamide) rather than the production of cADPR from ADP-ribosyl cyclase.

For separation, the denatured samples are loaded onto a gel of polyacrylamide, which is placed in an electrophoresis buffer with suitable electrolytes. Thereafter, a voltage (usually around 100 V, 10-20 V per cm gel length) is applied, which causes a migration of negatively charged molecules through the gel in the direction of the positively charged anode. The gel acts like a sieve. Small proteins migrate relatively easily through the mesh of the gel, while larger proteins are more likely to be retained and thereby migrate more slowly through the gel, thereby allowing proteins to be separated by molecular size. The electrophoresis lasts between half an hour to several hours depending on the voltage and length of gel used. The fastest-migrating proteins (with a molecular weight of less than 5 kDa) form the buffer front together with the anionic components of the electrophoresis buffer, which also migrate through the gel. The area of the buffer front is made visible by adding the comparatively small, anionic dye bromophenol blue to the sample buffer. Due to the relatively small molecule size of bromophenol blue, it migrates faster than proteins. By optical control of the migrating colored band, the electrophoresis can be stopped before the dye and also the samples have completely migrated through the gel and leave it. The most commonly used method is the discontinuous SDS-PAGE.

Sources: en.wikipedia.org

Frequently asked questions

What is semax derived from?

It is described as a synthetic analogue of the ACTH(4–10) fragment, a short segment of adrenocorticotropic hormone. Its sequence differs from that fragment and includes two proline residues, which influence stability and behaviour in solution.

Is semax an approved medicine outside Russia?

It appears in Russian pharmaceutical listings as a nasal formulation, but it is not an authorised medicine in the United States or the European Union. Outside those markets it is normally encountered as a research chemical rather than a prescription product.

What is known about its mechanism?

Laboratory and animal work points to melanocortin signalling and changes in neurotrophic factor levels, especially brain-derived neurotrophic factor. The exact receptor targets and the degree to which these findings transfer to humans are still unresolved.

Why are single-use aliquots recommended?

Each freeze-thaw cycle can degrade a fraction of the peptide and promote aggregation. Dividing a stock solution into single-use volumes removes repeated cycling as a variable. It also limits the time a thawed solution spends at room temperature.

Network